• Home
  • About
    • Who We Are
    • Mission
    • Values
  • Science & Pipeline
  • Patients
  • Leadership
  • Investors & Media
    • Overview
    • Press Releases
    • Events
    • Publications / Presentations
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Investor Resources
  • Careers
  • Contact Us
  • LinkedIn
  • Privacy
  • Terms of Use

Phase 2 Placeholder

by Kinnate Biopharma | Sep 12, 2020

RAF / exarafenib Monotherapy

by Kinnate Biopharma | Sep 12, 2020

Recent Posts

  • Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
  • Kinnate Biopharma Closes $98 Million Series C Financing
  • Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
  • Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
  • Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

Recent Comments

    Archives

    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • December 2019
    • April 2018

    Categories

    • Article
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    LinkedIn
    Expanded Access
    Contact
    Privacy
    Terms of Use
    © 2024 Kinnate Biopharma.

    On April 3, 2024, XOMA completed its acquisition of Kinnate. Visit XOMA.com